Boehringer Ingelheim Opens R&D Center In Shanghai; Sees Sales Growth From Products On NDRL Reimbursement List

SHANGHAI - Boehringer Ingelheim, the largest family-controlled pharma company, recently announced the opening of its Center of Competence in Shanghai. During the past year, the company invested €10 million to build the R&D center, which specializes in optimizing active pharmaceutical ingredients and chemical intermediates procured in China

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip